Mete, NuriyeÖztürk, İ. HakkıÇolpan, LeylaMete, Mahmut2024-04-242024-04-2419981300-01441303-6165https://search.trdizin.gov.tr/yayin/detay/6308https://hdl.handle.net/11468/25378In this study, plasma fibronectin and urine glycosaminoglycane levels were determined spectrophotometrically in 20 Rheumatoid arthritis, 10 Ankilosing spondilites, 22 osteoarthrosis and 21 healthy control subjects. The mean levels of Fibronectin (ug/ml) were 413.3±97 in patients with rheumatoid arthritis, 325.5+93.5 in ankilosing spondilites, 439.1±120.3 in osteoarthrosis and 302.2±60.1 in the control group. The ratio of urine glycosaminoglycan excretion to creatinine (g/mol) was 4.52±2.64 in patients with rheumatoid arthritis, 4.18±1.52 in patients with ankilosing spondilites, 2.72±1.19 in osteoarthrosis and 2.21 ±1.02 in the control group. Plasma Fibronectin lev-els were significantly higher in rheumatoid arthritis and osteoarthrosis when compared to the control group (p<0.001). The ratio of urinary glycosaminoglycans excretion to cre-atinine levels in patients with rheumatoid arthritis and ankilosing spondilites were significantly greater when compared with control group (p<0.001). Having established that plasma fibronectin levels and urine glycosaminoglycane/creati-nine ratio were important laboratory findings in rheumatic diseases, and it was decided to employ further research to englihten mecha-nisms that are still controversial.eninfo:eu-repo/semantics/openAccessPlasma fibronectin and urine glycosaminogiycane levels in rheumatic diseasesPlasma fibronectin and urine glycosaminogiycane levels in rheumatic diseasesOther2844374416308